Product Description
Oxymetazoline, a widely used intranasal decongestant, offers fast symptom relief, but little is known about the duration of effect. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29785414/)
Mechanisms of Action: ADRA1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Nasal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Santen
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Czech Republic, France, Germany, Hungary, Italy, Japan, Netherlands, Poland, Spain, United Kingdom
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Blepharophimosis|Blepharoptosis
Phase 1: Rosacea
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LIDRISE Study | P3 |
Recruiting |
Blepharophimosis|Blepharoptosis |
2026-02-01 |
|
| 101380003SA | P3 |
Unknown Status |
Blepharoptosis |
2025-12-31 |
|
| jRCT2031240257 | P1 |
Not yet recruiting |
Rosacea |
2024-11-30 |
|
| jRCT2031220394 | P3 |
Recruiting |
Blepharoptosis |
2024-09-30 |